---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035229"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:20:16.268248+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q2 net loss $36.9M, revenue down 28% YoY; Lilly collaboration expanded

## Summary
- Net loss $36.9M ($0.13/sh) vs $30.5M loss in Q2 2023; revenue $7.3M down from $10.1M.
- Partner-initiated program starts 93 cumulative (+16% YoY); molecules in clinic 14 (+56% YoY).
- Expanded Lilly collaboration to immunology, CV, neuroscience; Invetx to be acquired by Dechra for up to $520M.
- Abdera's ABD-147 received FDA IND clearance and Fast Track; AbCellera holds low-single-digit royalty and mid-single-digit equity.
- Cash and securities $697.6M plus ~$220M non-dilutive government funding; total liquidity >$900M.

## SEC filing metadata
- accession: 0001628280-24-035229
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828024035229/0001628280-24-035229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828024035229/abcl-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035229
- JSON: https://secwatch.observer/filing/0001628280-24-035229.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.